CEO Abizer Gaslightwala discusses the Company’s recent announcement around its ADC pipeline expansion and IP strategy Company also discusses its lead ADC program, AKTX-101, and its planned IND and CTA submissions as it advances towards first-in-human studies Watch the “What This Means” video here TAMPA, Fla. and LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-sp ...

CEO Abizer Gaslightwala discusses the Company’s recent announcement around its ADC pipeline expansion and IP strategy Company also discusses its lead ADC program, AKTX-101, and its planned IND and CTA submissions as it advances towards first-in-human studies Watch the “What This Means” video here TAMPA, Fla. and LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company pioneering next-generation antibody drug conjugates (ADCs) powered by novel RNA-sp ...

Core Viewpoint - Akari Therapeutics is advancing its next-generation antibody drug conjugates (ADCs) with a focus on its proprietary PH1 spliceosome-modulating payload, aiming to initiate first-in-human trials for its lead program, AKTX-101, by late 2026 or early 2027 [2][4]. Company Overview - Akari Therapeutics is an oncology biotechnology company specializing in ADCs that utilize a unique payload, PH1, which targets RNA splicing [4]. - The company has developed a platform that allows for the generation and optimization of ADC candidates tailored to specific antigen targets [4]. Lead Programs - The lead program, AKTX-101, targets the Trop2 receptor on cancer cells and is designed to deliver the PH1 payload directly to tumors with minimal off-target effects [2][4]. - AKTX-101 has shown significant activity in preclinical studies, leading to prolonged survival compared to traditional ADCs [4]. - The company is also advancing AKTX-102, another ADC program focused on gastrointestinal (GI) and lung cancers [2][4]. Upcoming Events - Akari Therapeutics will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026, where CEO Abizer Gaslightwala will present a corporate overview and updates on the company's programs [1][3].

Core Insights - Akari Therapeutics is expanding its pipeline with a new ADC candidate, AKTX-102, targeting CEACAM5, a significant solid tumor marker in oncology [1][3] - The company has filed a U.S. provisional patent application for AKTX-102, which utilizes a proprietary PH1 spliceosome payload to enhance therapeutic efficacy [1][5] Pipeline and Product Development - AKTX-102 is designed to address CEACAM5, which is expressed in 80-90% of gastrointestinal cancers and has been linked to aggressive cancer subtypes [2][4] - The ADC combines a novel antibody construct with the PH1 payload, aiming to improve tumor cell killing and activate immune responses [3][4] Intellectual Property and Innovation - The new patent filing enhances Akari's intellectual property portfolio, which includes previous filings focused on novel mechanisms and combination strategies [5][6] - Akari's patent estate is expected to support the development of multiple first- and best-in-class ADC candidates across various cancer targets [6] Market Opportunity and Challenges - CEACAM5 has been a challenging target in oncology due to its complex biology, but Akari's approach aims to overcome these hurdles [7][8] - The company’s strategy includes addressing CEACAM5's role as an immunosuppressive checkpoint, which has historically limited therapeutic success [8][9] Clinical Development and Future Plans - Akari is advancing its lead program, AKTX-101, towards IND/CTA submission and first-in-human trials, with a goal to initiate by late 2026 or early 2027 [10][13] - The company is also pursuing partnerships to leverage its unique PH1 payload and ADC approach [13]

Core Insights - Akari Therapeutics is progressing towards becoming a clinical-stage oncology company in 2026, with significant milestones achieved in 2025 [3][4] - The company is developing a novel payload, PH1, for its antibody-drug conjugates (ADCs), which has shown promising preclinical efficacy and safety [4][6] - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has demonstrated significant activity and prolonged survival in preclinical studies [6] Company Developments - In 2025, Akari established a strategic manufacturing partnership with WuXi Biologics to support clinical readiness [4] - The company plans to initiate its First-in-Human clinical trial for AKTX-101 by late 2026 or early 2027 [6] - Akari is also advancing another ADC candidate, AKTX-102, targeting a novel antigen relevant in gastrointestinal and lung cancers [6] Scientific Innovations - The PH1 payload is designed to disrupt RNA splicing within cancer cells, leading to cancer cell death while activating the immune system [6] - AKTX-101 has the potential for synergy with checkpoint inhibitors, showing prolonged survival both as a single agent and in combination therapies [6] - The PH1 payload has demonstrated activity against cancer cells with key oncogenic drivers such as KRAS, BRAF, and ARV7 [6]

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing [3] - The company's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors with minimal off-target effects [3] - AKTX-101 has shown significant activity and prolonged survival in preclinical studies compared to traditional ADCs, and it has the potential to be synergistic with checkpoint inhibitors [3] Strategic Priorities - Akari Therapeutics aims to initiate IND enabling studies for AKTX-101, with a goal of starting its First-In-Human trial by late 2026 or early 2027 [3] - The company is also advancing AKTX-102, an ADC targeting a novel antigen relevant in gastrointestinal and lung cancers [3] Upcoming Presentation - Abizer Gaslightwala, President and CEO of Akari Therapeutics, will present at the 2026 Biotech Showcase on January 13, 2026, at 9:30 AM PST [1][2] - The presentation will cover an overview of Akari's ADC platform, strategic priorities, and key milestones for 2026 [1]

Core Viewpoint - Akari Therapeutics has announced a definitive agreement for the issuance and sale of approximately 12.6 million American Depositary Shares (ADSs) and unregistered warrants, with significant participation from its Directors, Officers, and Executive Management, aimed at supporting its oncology drug development initiatives and improving its capital structure [1][4][6]. Group 1: Offering Details - The offering includes 10,043,774 ADSs in a registered direct offering priced at $0.3883 per ADS, along with unregistered Series G warrants [3]. - A concurrent private placement will issue unregistered pre-funded warrants for 2,563,713 ADSs at a combined price of $0.4041 per ADS [3]. - The gross proceeds from the offering are expected to be around $5 million, with over $1 million coming from new cash investments by the Company's Directors, Officers, and Executive Management [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for ongoing research and development, working capital, and general corporate purposes [4]. Group 3: Debt Conversion - Existing note holders have agreed to convert approximately $2.5 million of the Company's outstanding debt into unregistered pre-funded warrants and warrants to purchase 6,409,410 ADSs at a combined exchange price of $0.4041 per ADS [5]. Group 4: Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs), with its lead candidate AKTX-101 targeting the Trop2 receptor on cancer cells [10]. - The novel payload PH1 is designed to disrupt RNA splicing within cancer cells, showing significant activity and prolonged survival in preclinical studies compared to traditional ADCs [10].

Core Insights - Akari Therapeutics has announced promising preclinical data for its antibody-drug conjugate (ADC) AKTX-101, which targets Trop2 and shows potential in treating K-Ras G12V mutated pancreatic cancer, a highly lethal form of cancer with low survival rates [1][6] Industry Overview - Pancreatic cancer is one of the deadliest cancers, with approximately 60,000 new diagnoses and around 50,000 deaths annually in the U.S. The most common type, pancreatic ductal adenocarcinoma (PDAC), has limited treatment options, especially for K-Ras G12V mutation-driven tumors [2][3] Current Treatment Landscape - The standard treatments for K-Ras G12V-driven PDAC, such as FOLFIRINOX and gemcitabine plus nab-paclitaxel, yield poor outcomes with overall survival rates of 1.5 years and 1.3 years, respectively. There is a significant unmet need for targeted therapies in this area [3][4] AKTX-101 Mechanism and Efficacy - AKTX-101 is designed to deliver a novel RNA spliceosome modulating payload, PH1, to cancer cells expressing Trop2. This mechanism disrupts RNA splicing, which is crucial for cancer cell survival and proliferation. The ADC has shown significant cytotoxic potency in preclinical models, outperforming other investigational therapies [4][5] Future Development Plans - The company plans to present the preclinical data at a scientific conference and is advancing AKTX-101 towards a first-in-human trial expected to start in late 2026, with preliminary safety and efficacy data anticipated in 2027 [7]

Core Insights - Akari Therapeutics is focused on developing novel payloads for antibody drug conjugates (ADCs), specifically highlighting its innovative PH1 payload and its dual mechanism of action [1][3] - The company aims to advance differentiated therapies for oncology patients through its next-generation ADC discovery platform [1][3] Company Overview - Akari Therapeutics is an oncology biotechnology company that specializes in next-generation spliceosome payload ADCs [3] - The company utilizes an innovative ADC discovery platform to generate and optimize ADC candidates for various targets [3] Product Innovation - The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, which has shown potential to induce cancer cell death and activate immune responses [3] - Preclinical studies of AKTX-101, an ADC utilizing the PH1 payload, have demonstrated significant activity and prolonged survival compared to traditional ADCs [3] - AKTX-101 has shown potential synergy with checkpoint inhibitors, exhibiting prolonged survival both as a single agent and in combination with these inhibitors [3]

Core Insights - Akari Therapeutics has appointed Kameel D. Farag as Interim Chief Financial Officer, bringing over 20 years of experience in biopharma and global finance [1][2][4] - The company is focused on developing novel antibody drug conjugates (ADCs) that utilize a unique spliceosome modulator payload, aiming to disrupt cancer cell survival [2][7] Company Overview - Akari Therapeutics is an oncology biotechnology company specializing in next-generation spliceosome payload ADCs, with a platform capable of generating and optimizing ADC candidates for various targets [7] - The lead asset, AKTX-101, has shown significant preclinical activity and prolonged survival compared to traditional ADCs, with potential synergy with checkpoint inhibitors [7] Leadership Background - Kameel D. Farag previously served as CFO at Aspen Neuroscience, where he tripled the company's headcount and secured over $150 million in financing [4] - Farag has also held senior finance roles at Ionis Pharmaceuticals and Amgen, contributing to substantial revenue growth and operational improvements [4]